In particular, TNF alpha inhibitors (etanercept and adalimumab), IL-17 inhibitors (ixekizumab, secukinumab), and IL-12/23 inhibitors (ustekinumab) are available for pediatric use [30] and do not appear to have any interactions from the point of view of psoriasis metabolic complications. This evidence concerns the gene IL17A and psoriasis.